Volition is a leading epigenetics biomarker company, renowned for its proprietary immunoassay approach to profiling cell-free circulating nucleosomes. Our fully quantitative assays have demonstrated significant value in preclinical and clinical drug development programs across multiple therapeutic areas, including oncology and inflammatory diseases. Our fee-for-service portfolio, Nu.Q® Discover, encompasses a range of assays targeting biomarkers associated with epigenetic inhibitors (HDACi, LSDi, EZH2i, EEDi), as well as innate immune activation (NETosis). Nu.Q® assays effectively correlate with disease and tumour burden, making them ideal for use as surrogate endpoint markers of treatment response, minimal residual disease, and relapse monitoring. Our development pipeline includes assay development, a novel proteomics approach to epigenetic profiling of circulating nucleosomes using Mass Spec, and Toxicity Monitoring assays.
Discover more at www.volition.com and join us at the Next Generation Immuno-Oncology Conference to explore how we can support your projects.
We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.
With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMab™ Mouse), and in vivo/in vitro preclinical validation studies. Together, we discover innovative medicines for a better, healthier world.
Veracyte is a pioneering, global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and accelerate time to appropriate treatment. Veracyte offers customized multi-omics tools and expertise to our biopharmaceutical partners, helping them advance their therapeutic discovery, development and commercialization programs.
With over 15 years of experience in genetic and epigenetic clinical research, EpigenDx offers high quality products and laboratory services focused on DNA methylation analysis, gene expression profiling, and mutation analysis. Our scientific teams carefully evaluate each project and establish analysis procedures using best fit technologies, including NGS, Pyrosequencing, RT-PCR, digital PCR, and GeneChip Microarray. Our popular services include Line-1 global methylation tests and Foxp3-TSDR analysis for epigenetic immunotherapy. Our GLP compliant and CLIA certified services make us the perfect partner during pre-clinical research and diagnostic test development.
At Olink Proteomics, we revolutionize biomarker discovery with our high-multiplex Proximity Extension Assay technology. Specializing in the human plasma proteome, we provide high-throughput, sensitive, and specific analysis from minimal sample volumes. Our mission is to advance proteomics across various diseases, bridging biomarker workflows from discovery to clinical utility. Trusted in over 1,500 publications, Olink is at the forefront of uncovering vital insights into human health and disease.
TransCure bioServices (TCS) provides predictive in vivo pharmacology expertise for drug pre-clinical candidate selection in the fields of infectious, cancer (IO, PDX), inflammation, vaccine and immune disease areas. We are the only preclinical CRO providing commercially HIV, immuno-oncology (IO) therapy, PDX, IBD, vaccine and autoimmune mouse models with a fully functional reconstituted HUMAN IMMUNE SYSTEM (hu-mouse models). We co-design study protocols/experiments performing the ordered studies and providing comprehensive data collection, data analysis and reports.
Established in 2004, LARVOL combines the best of artificial and human intelligence to deliver expertly curated and personalized data solutions to medical affairs, competitive intelligence, commercial, and R&D teams within the pharmaceutical and biotech industry.
GemPharmatech is a global company providing high-quality products and model systems for discovery, testing, development and production of new drugs and therapeutic solutions. GemPharmatech is one of the best one-stop service center for production, distribution, and phenotyping of gene-modified mouse models for partners across the world. With advance gene editing technology, GemPharmatech has created and produced a large collection of over 14,000 transgenic mouse models for therapeutic applications.
